[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN113491337A - Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof - Google Patents

Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof Download PDF

Info

Publication number
CN113491337A
CN113491337A CN202110665006.0A CN202110665006A CN113491337A CN 113491337 A CN113491337 A CN 113491337A CN 202110665006 A CN202110665006 A CN 202110665006A CN 113491337 A CN113491337 A CN 113491337A
Authority
CN
China
Prior art keywords
chain fatty
metabolism
intestinal
composition
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110665006.0A
Other languages
Chinese (zh)
Inventor
刘斐童
王园园
胡瑞标
陈桔淳
郑雨星
赵飞
彭倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biostime Guangzhou Health Product Co ltd
Original Assignee
Biostime Guangzhou Health Product Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostime Guangzhou Health Product Co ltd filed Critical Biostime Guangzhou Health Product Co ltd
Priority to CN202110665006.0A priority Critical patent/CN113491337A/en
Publication of CN113491337A publication Critical patent/CN113491337A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/19Dairy proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38Other non-alcoholic beverages
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52Adding ingredients
    • A23L2/66Proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40Transferrins, e.g. lactoferrins, ovotransferrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention discloses a composition for regulating the metabolism of infant intestinal short-chain fatty acid, which comprises the following components: 3-6 parts of lactoferrin, 0.3-1 part of animal bifidobacterium powder and 40-60 parts of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 107~108CFU/part by weight. The composition disclosed by the invention can increase the total content of infant intestinal short-chain fatty acids and the content of acetic acid by compounding lactoferrin, bifidobacterium animalis and galactooligosaccharides, is beneficial to adjusting the metabolism of the infant intestinal short-chain fatty acids, and can be applied to preparation of medicines or foods with the functions of adjusting the metabolism of the infant intestinal short-chain fatty acids, increasing the content of the intestinal short-chain fatty acids or increasing the content of the intestinal acetic acid.

Description

Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof
Technical Field
The invention relates to the field of food, and in particular relates to a composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof.
Background
The intestinal flora coexists with the body and exerts a great deal of influence on the body in the aspects of metabolism, development and maturation of immune function, protection of intestinal tract and the like. The effects on the metabolism of the body, such as the production of short-chain fatty acids, mainly acetate, propionate and butyrate, can provide energy and maintain the growth and development of the gastrointestinal tract, and are very important for the intestinal health of infants. Some intestinal flora may synthesize vitamins, such as vitamin K and other vitamin B groups, that have important effects on infants. Some bacteria in the intestinal tract can also produce conjugated linoleic acid, which plays an important role in the normal growth and development of newborns, and is associated with obesity, diabetes and immune function. The gut flora may also influence the blood concentration of tryptophan, an essential amino acid, by the kynurenine pathway, which is important in the development of the central nervous system. The interaction between the intestine and the brain forms a brain-intestine axis, and integrates the mechanisms of nerve, immunity and endocrine, while the intestinal flora can play a role similar to signal molecules in the brain-intestine axis and play a role in regulating various aspects such as immune function, central nervous system and gastrointestinal function in the early life. The intestinal flora can influence the colonization and reproduction of pathogenic bacteria through biological antagonism, thereby protecting organisms from being damaged by the pathogenic bacteria. The intestinal bacteria have regulating effect on both innate immunity and adaptive immunity. Through aseptic animal experimental studies, it has been demonstrated that intestinal microorganisms are essential for maintaining normal intestinal morphology and immune maturation, and mice that survive aseptic conditions exhibit impaired development of the intestinal immune system and a defect in oral immune tolerance. Bifidobacteria in the recombinant gut flora may restore the oral tolerance during neonatal period.
Intestinal microorganisms are an important part of the human body and play a very important role in the development, function and regulation of the human immune system in various ways from birth. The evolutionary symbiotic relationship between humans and intestinal microorganisms has numerous benefits to humans, including regulation of host immunity, production of vitamin K and vitamin B, protection of the gut from pathogens, enhancement of gut integrity, and production of Short Chain Fatty Acids (SCFAs), metabolites. Short chain fatty acids are produced by intestinal flora by fermenting carbohydrates, mainly acetic acid, propionic acid, butyric acid, etc. Short Chain Fatty Acids (SCFA) mediate the interaction between gut flora and host metabolism, and the effects of both prebiotics and probiotics depend on SCFA. Short chain fatty acids are thought to mediate communication between the gut flora and the immune system, inhibiting the proliferation of certain bacteria by lowering the pH of the gut, and are critical to gut homeostasis. SCFAs can conduct signals through G protein sensitive G protein coupled receptors, and SCFAs circulating in blood can affect tissue specific acetylation of histones 3 and 4, and induce epigenetic change of genome; the content of SCFAs in intestinal tracts is increased through special diet, so that the diabetes of non-obese diabetic mice can be prevented; during pregnancy, SCFAs can cause epigenetic imprints in the uterus and prevent allergic diseases in the infant's airways; SCFAs also regulate blood brain barrier and neuroimmune endocrine function. Short chain fatty acids can inhibit Histone Deacetylases (HDACs), which are involved in regulating gene expression in many diseases and promoting the onset of disease. SCFAs play a beneficial role in the metabolism and function of adipose tissue, skeletal muscle and liver stroma and contribute to improved insulin sensitivity.
Acetate, propionate, butyrate are the major SCFAs, and lactate, succinate are precursors of SCFAs, produced mediated by specific intestinal microbial enzymes, at concentrations that are highest in the cecum and proximal colon, and are a source of colonic cellular energy. Animal and human data suggest that acetate affects host energy and substrate metabolism by regulating intestinal hormone secretion and metabolism substrates such as glucagon-like peptide-1 and peptide YY. Appetite is affected by reducing systemic lipolysis, levels of systemic inflammatory cytokines, increasing energy expenditure and fat oxidation. Acetate may also be produced by deacetylation of endogenous proteins, such as histones. Acetate plays a key role in maintaining intracellular levels of acetyl-coa, and disturbances in acetate metabolism are associated with several human diseases. Short Chain Fatty Acid (SCFA) produced by fermenting dietary fiber by intestinal flora has immunoregulation function.
There is currently no study on compositions that increase the content of short chain fatty acids in the infant's intestinal tract.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a composition for regulating the metabolism of short-chain fatty acids in the intestinal tract of infants and application thereof.
In order to achieve the purpose, the invention adopts the technical scheme that: a composition for regulating the metabolism of short chain fatty acids in the infant's intestinal tract, comprising the following components: 3-6 parts of lactoferrin, 0.3-1 part of animal bifidobacterium powder and 40-60 parts of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 107~108CFU/part by weight.
The inventor finds that the composition disclosed by the invention can increase the total content of infant intestinal short-chain fatty acids and the content of acetic acid by compounding lactoferrin, bifidobacterium animalis and galactooligosaccharides, and is beneficial to regulating the metabolism of the infant intestinal short-chain fatty acids.
Preferably, the composition comprises the following components: 5.5 parts by weight of lactoferrin, 0.5 part by weight of animal bifidobacterium powder and 50 parts by weight of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 107~108CFU/part by weight. The effect of increasing the total content of short chain fatty acid and the content of acetic acid in the intestinal tract of the infant by matching the three components in the proportion is better than that of two or one of the three components.
The invention also aims to provide the application of the composition for regulating the metabolism of the infant intestinal short-chain fatty acid in preparing a medicament or food with the function of regulating the metabolism of the infant intestinal short-chain fatty acid; preferably, the food is prepared milk powder, health-care products or drinks.
The invention also aims to provide application of the composition for regulating the intestinal short-chain fatty acid metabolism of infants in preparing medicines or foods with the function of increasing the intestinal short-chain fatty acid content or increasing the intestinal acetic acid content. Preferably, the food is prepared milk powder, health-care products or drinks.
The invention also aims to provide the modified milk powder, which comprises the composition for regulating the metabolism of the short-chain fatty acid in the intestinal tract of the infant.
Preferably, the weight percentage of the composition for regulating the metabolism of the infant intestinal short-chain fatty acid in the modified milk powder is 3-6%. When the composition is added into prepared milk powder, the metabolism of short-chain fatty acids in the intestinal tract of infants can be effectively regulated, and the intestinal health is maintained.
The invention has the beneficial effects that: the composition is prepared by compounding lactoferrin, animal bifidobacteria and galactooligosaccharides, can increase the total content of short-chain fatty acids and the content of acetic acid in the intestinal tract of infants, is favorable for adjusting the metabolism of the short-chain fatty acids in the intestinal tract of infants, and can be applied to preparation of medicines or foods with the functions of adjusting the metabolism of the short-chain fatty acids in the intestinal tract of infants, increasing the content of the short-chain fatty acids in the intestinal tract or increasing the content of the acetic acid in the intestinal tract.
Drawings
FIG. 1 is a graph showing the acetate content in a sample;
FIG. 2 is a graph showing the total short chain fatty acid content in the samples.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
The sources of the raw materials are as follows:
galacto-oligosaccharide: DP2-DP8, available from Quantum Kogaku;
lactoferrin: purchased from warranwood warenburg;
animal bifidobacterium powder: BB12 from Kehansen.
10 infants of 0-6 months are recruited in a company, the information such as the diet condition of the infants, the using condition of probiotics and the like is investigated, and 4 volunteers meeting the experimental requirements are selected from the information: feeding with pure breast milk, adding no supplementary food, preventing diarrhea or constipation in one month, and collecting feces samples after filling informed consent without using probiotics, medicine and antibiotics.
Three test groups were set:
1. galacto-oligosaccharides (GOS) group: 50mg of galacto-oligosaccharide;
2. lactoferrin + bifidobacterium animalis (LF + BB12) group: 5.5Lactoferrin and 0.5mg Bifidobacterium animalis powder (containing Bifidobacterium animalis 10. mu.m. in it)7CFU);
3. Lactoferrin + bifidobacterium animalis + galactooligosaccharides (LF + BB12+ GOS) group: 5.5mg of lactoferrin, 0.5mg of animal bifidobacterium powder (containing about bifidobacterium animalis 10 therein)7CFU) and 50mg galacto-oligosaccharide.
Preparing a trace element solution: scale FeSO4·7H2O 3.68g、MnSOH2O 1.159g、ZnSO7H2O 0.44g、CoCl6H2O 0.12g、NiCl2 0.10g、CuSO5H2O0.098 g and Mo7(CH4)6O24H2O0.017 g, dissolved in 1L of sterile water.
Preparing a buffer solution: MgCl2·6H2O 0.1g、NaSO4 0.1g、CaCl2·2H20.728g of O, 0.4g of urea, 0.45g of KCl, 0.47g of NaCl and Na2HPO4 2.824g、NaHCO39.24g of the mixture, 0.001mg of the Resazurin and 10ml of the trace element solution are mixed, the volume is determined to be 1L, and the mixture is sterilized for later use.
The excrement sample is tested one by one, firstly, the excrement sample is filtered, and the prepared buffer solution and the sample are added: buffer 1: 4, preparing the excrement homogenate. Taking 1ml of excrement homogenate to be filled into fermentation vials containing different raw materials, adding 3ml of buffer solution, covering the caps, and then carrying out anaerobic fermentation at 37 ℃. During the fermentation, the amount of short chain fatty acid was measured by gas phase at 4h, 8h,24h, and 48h, and the test results are shown in tables 1 and 2 and fig. 1 and 2.
TABLE 1 acetate content in the samples (unit: mmol/L)
Time GOS LF+BB12 LF+BB12+GOS
4h 15.29±12.95 7.25±3.90 31.09±15.85
8h 35.19±30.25 9.55±4.12 52.66±34.70
24h 51.14±24.33 15.95±3.56 76.68±31.73
48h 51.66±22.25 27.27±11.47 85.84±19.73
TABLE 2 Total short chain fatty acid content (unit: mmol/L) in the samples
Time GOS LF+BB12 LF+BB12+GOS
4h 16.20±13.11 7.56±4.10 29.12±13.15
8h 36.23±1.840 10.84±4.38 60.06±2.291
24h 51.43±2.674 19.71±4.50 80.23±3.120
48h 57.72±1.569 33.69±13.48 92.42±1.469
From tables 1 and 2 and fig. 1 and 2, it can be seen that the addition of GOS significantly increased the level of intestinal acetic acid over time by fermentation with the intestinal flora of pure breast-fed infants. The lactoferrin + bifidobacterium animalis + galacto-oligosaccharides (LF + BB12+ GOS) group started at 8h and produced higher total short chain fatty acids than the GOS group and LF + BB12 group, and than the sum of the other two groups, with significant differences, and also significantly higher at 24h and 48h than the other groups. Therefore, the composition can improve the generation amount of total short-chain fatty acid in the in-vitro simulated fermentation process, and can balance the content of key fatty acid metabolites such as acetic acid, propionic acid and butyric acid in the intestinal tracts of infants. Short chain fatty acids can lower the pH of the intestinal tract to inhibit proliferation of certain bacteria; the acetate has anticancer effect and can improve intestinal function. It can therefore be assumed that a composition comprising lactoferrin, galactooligosaccharides and bifidobacterium animalis is beneficial for healthy development of the infant's gut.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.

Claims (8)

1. A composition for regulating the metabolism of short chain fatty acids in the infant's intestinal tract, comprising the following components: 3-6 parts of lactoferrin, 0.3-1 part of animal bifidobacterium powder and 40-60 parts of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 107~108CFU/part by weight.
2. The composition for modulating the metabolism of infant intestinal short chain fatty acids according to claim 1, wherein the composition comprises the following components: 5.5 parts by weight of lactoferrin, 0.5 part by weight of animal bifidobacterium powder and 50 parts by weight of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 107~108CFU/part by weight.
3. Use of the composition for regulating the metabolism of infant intestinal short-chain fatty acids according to claim 1 or 2 for preparing a medicament or food with the function of regulating the metabolism of infant intestinal short-chain fatty acids.
4. The use according to claim 3, wherein the food product is a reconstituted milk powder, a nutraceutical or a beverage product.
5. Use of a composition for modulating the intestinal short chain fatty acid metabolism in infants and young children according to claim 1 or 2 for the manufacture of a medicament or food product having an increased intestinal short chain fatty acid content or an increased intestinal acetic acid content.
6. The use of claim 5, wherein the food product is a reconstituted milk powder, a nutraceutical, or a beverage product.
7. Modified milk powder comprising a composition for modulating the metabolism of short chain fatty acids in the infant's intestine according to claim 1 or 2.
8. The modified milk powder of claim 7, wherein the composition for regulating the metabolism of infant intestinal short chain fatty acids is present in the modified milk powder in an amount of 3 to 6% by weight.
CN202110665006.0A 2021-06-15 2021-06-15 Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof Pending CN113491337A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110665006.0A CN113491337A (en) 2021-06-15 2021-06-15 Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110665006.0A CN113491337A (en) 2021-06-15 2021-06-15 Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof

Publications (1)

Publication Number Publication Date
CN113491337A true CN113491337A (en) 2021-10-12

Family

ID=77997616

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110665006.0A Pending CN113491337A (en) 2021-06-15 2021-06-15 Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof

Country Status (1)

Country Link
CN (1) CN113491337A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115989836A (en) * 2022-11-29 2023-04-21 黑龙江飞鹤乳业有限公司 Nutritional composition containing lactoferrin and probiotics, food and application

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2004201C2 (en) * 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
US20160095339A1 (en) * 2014-10-01 2016-04-07 Mead Johnson Nutrition Company Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile
CN106820156A (en) * 2017-02-17 2017-06-13 福建康是美生物科技有限公司 A kind of probiotic composition of regulating intestinal canal flora health
US20190029306A1 (en) * 2016-01-26 2019-01-31 Nestec S.A. Composition for use in the prevention and/or treatment of skin conditions and skin diseases
US20190060334A1 (en) * 2016-01-26 2019-02-28 Nestec S.A. Compositions with specific oligosaccharides to prevent or treat allergies
CN109430666A (en) * 2018-10-15 2019-03-08 威海养经堂医药科技有限公司 A kind of Freeze-dry Powder of Probioctics solid beverage

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2004201C2 (en) * 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
US20160095339A1 (en) * 2014-10-01 2016-04-07 Mead Johnson Nutrition Company Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile
US20190029306A1 (en) * 2016-01-26 2019-01-31 Nestec S.A. Composition for use in the prevention and/or treatment of skin conditions and skin diseases
US20190060334A1 (en) * 2016-01-26 2019-02-28 Nestec S.A. Compositions with specific oligosaccharides to prevent or treat allergies
CN106820156A (en) * 2017-02-17 2017-06-13 福建康是美生物科技有限公司 A kind of probiotic composition of regulating intestinal canal flora health
CN109430666A (en) * 2018-10-15 2019-03-08 威海养经堂医药科技有限公司 A kind of Freeze-dry Powder of Probioctics solid beverage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
赵方舟,等: "早期乳铁蛋白干预对哺乳仔猪盲肠菌群结构、短链脂肪酸含量及黏膜炎症因子水平的影响", 南京农业大学学报 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115989836A (en) * 2022-11-29 2023-04-21 黑龙江飞鹤乳业有限公司 Nutritional composition containing lactoferrin and probiotics, food and application

Similar Documents

Publication Publication Date Title
JP6985231B2 (en) Use of purified 2'-fucosyllactoce, 3-fucosyllactose, and lactodifucotetraose as prebiotics
CN103384529B (en) Be suitable for the method and composition controlling animal blood glucose
CN101188947B (en) Use of polydextrose for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
CN113475720B (en) Application of osteopontin in increasing intestinal flora diversity and increasing intestinal short-chain fatty acid content
Noor et al. Exploring the impact of the gut microbiome on obesity and weight loss: a review article
CN114558038B (en) Probiotic composition for losing weight and reducing fat as well as preparation method and application thereof
AU2006244703B2 (en) Method of improving immune function in mammals using 3-HPA producing lactobacillus strains in combination with medium chain triglyceride oil
Suh et al. Inhibitory effect of galactooligosaccharide on skin pigmentation
MX2007012530A (en) Use of lactobacillus rhamnosus gg for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant.
CN115068591B (en) Probiotic composition containing osteopontin
CN113491337A (en) Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof
CN117731007A (en) Pumpkin seed protein composition and application thereof
US20040105849A1 (en) Treatment for SMA disease
Chaturvedi et al. Human milk oligosaccharides: potential upshot on health at early life stage development
Chen et al. A prebiotic formula improves the gastrointestinal bacterial flora in toddlers
CN112806577B (en) Prebiotic probiotic synergistic combinations for butyric acid production
CN113966845A (en) Nutritional composition for promoting intestinal health of infants
CN113476463A (en) Prebiotic composition and application thereof
Gao et al. Importance of gut microbiota in health and diseases of new born infants
YASMIN et al. Effect of honey supplementation on plasma levels of short chain fatty acids in malnurished children
CN118633735A (en) Application of the composition in preparing a product for improving constipation
KR102660139B1 (en) Fermentation Products Comprising Short Chain Fatty Acids And Use Of Improving, Preventing Or Treating Overweight Thereof
CN112805010B (en) Dietary fiber for treating patients with methylmalonic acidemia and propionic acidemia
Tyagi 9. Role of prebiotics and probiotics in immunity
Miller Update on the Gut Microbiome for the Primary Care Clinician.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20211012

RJ01 Rejection of invention patent application after publication